Pulmatrix Announces First Quarter 2026 Financial Results
Pulmatrix reported a Q1 2026 net loss of $1.17 million and $3.3 million in cash, noting a going concern assumption while awaiting a strategic transaction. The company highlighted its March 26 merger agreement with Eos SENOLYTIX, a privately held biotech focused on aging-related diseases, which is expected to close in Q3 2026.
Key figures
- Net Loss
- 1172000
- Revenue
- 0
- Deal Value Usd
- 1000000
- Cash And Equivalents
- 3324000
- Rd expense
- 3000
- Gna expense
- 1289000
- Patents granted
- 146
- Patents pending
- 48
- Common stock interest
- 6%
- Total operating expense
- 1292000
- Preferred stock proceeds
- 1000000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.